CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.
Follow CTMX
CytomX Therapeutics, Inc. (CTMX) EV/Sales
As of 16 October 2026, CytomX Therapeutics, Inc. (CTMX) trades at a EV/Sales of 9.3×. Over the past ten years it has ranged from −13.6× (October 2015) to 46.7× (September 2016); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.0× | — |
| FY2024 | −0.1× | — |
| FY2023 | −0.5× | — |
| FY2022 | −1.6× | — |
| FY2021 | −0.6× | — |
| FY2020 | −0.1× | — |
| FY2019 | 1.5× | (55.27%) |
| FY2018 | 3.2× | (46.55%) |
| FY2017 | 6.1× | (55.72%) |
| FY2016 | 13.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 27.0× | 95.52% |
| Mar 2026 | 13.8× | 131.34% |
| Dec 2025 | 6.0× | 75.26% |
| Sep 2025 | 3.4× | 245.57% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| CTMX CytomX Therapeutics, Inc. | 9.3× |
| ACRS Aclaris Therapeutics, Inc. compare | 47.1× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | 759× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)